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Objectives: Pharmaceutical full-line wholesalers carry out a variety of main func-
tions. One of these is the financing function. Pharmaceutical full-line wholesal-
ers stock and distribute the complete assortment of products in range and depth. 
Moreover, they acquire ownership over the medicinal products when purchasing 
them from the manufacturers and pass on ownership to pharmacies when they 
are delivered. Thus, the analysis aims to draw a comprehensive picture of the pre-
financing function, expressed in terms of working capital, of the pharmaceutical 
wholesale sector in Europe. MethOds: The necessary data was provided by the 
European Association of Pharmaceutical Full-line Wholesalers (GIRP). The study 
analysed core indicators representative for all countries of the European Union 
plus Croatia, Norway and Switzerland (EU-25 + 3), with the exception of Malta and 
Cyprus as no full-line wholesalers are operating in the latter. Results: In the ana-
lysed countries, 935 pharmaceutical full-line wholesalers operate 1,220 warehouses, 
serving 171,767 retail and hospital pharmacies and dispensing doctors and sup-
ply 520 million people. In 2012, pharmaceutical full-line wholesalers generated a 
total turnover of € 130 billion in the EU-25 + 3. Pharmaceutical full-line wholesalers 
assume a pre-financing function towards manufacturers and pharmacies that is 
not offered by other distribution models. In the EU-25 + 3 alone they pre-financed 
on average € 12.2 billion over a period of 35 days. In total, this sum is pre-financed 
approximately ten times per year. cOnclusiOns: Pharmaceutical full-line whole-
salers pre-finance the entire retail market of medicinal products, guarantee the 
continuous supply of all medicinal products and secure the cash flow of social 
insurers. The funding and holding of buffer stocks, the resulting working capital 
and ownership that goes with wholesaling services are vital for an effective and 
efficient functioning of the health care industry in Europe.
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Objectives: The global biopharmaceutical industry is facing a biologics “pat-
ent cliff” between 2013 and 2020, which will leave approximately $54 billion in 
drug revenue, without patent protection. In order to achieve success with these 
biosimilar agents, it is critical that manufacturers/marketers target the highest 
potential global markets. The objective of this research is to provide a framework 
for identifying the markets with the highest potential for biosimilar adoption and 
utilization. MethOds: A review of literature, research reports, and review articles 
was conducted, along with a panel discussion of industry thought leaders in bio-
similars. Key indicators of biosimilar market potential were identified, evaluated, 
and prioritized. A systematic approach was developed to score each key indicator, 
and a mathematical approach adopted to aggregate the market scores. A series 
of 20 country markets were evaluated and ranked in order of biosimilar market 
potential. Results: Key indicators of biosimilar market potential were separated 
into three categories: 1.) Originator-drug indicators including originator sales, 
reimbursement level, and reimbursement status. 2.) Market indicators including 
rate of uptake of currently available biosimilars, payer cost-containment mecha-
nisms, and future biosimilar outlook. 3.) Regulatory indicators including barriers 
to marketing authorization based on the complexity of required data packages, 
and the risks associated with the development of clinical programs. Secondary 
research of public domain information was conducted on each of 20 countries, in 
order to obtain the data to populate the key indicators for market potential. Each 
country achieved a score based on the data, and was ranked based on biosimilar 
market potential. cOnclusiOns: The process demonstrates a rational approach 
to identifying and sequencing of biosimilar market potential, which can be used to 
inform clinical-development and market-access plans. Also, in practical applica-
tion for a manufacturer/marketer, “resource indicators” of market-specific assets 
should be included.
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Objectives: To investigate whether trends exist in drug prices of products approved 
by the UK NICE with a Patient Access Scheme in other key EU countries in the last 
2 years. MethOds: Expensive new pharmaceuticals that are not deemed cost-
effective by NICE in the first instance, can often still become recommended with 
a Patient Access Scheme. It is a trend that the type of scheme offered is becoming 
purely financial-based, with the last 17 schemes approved offering a simple dis-
count. Although these discounts are ‘commercial in confidence’, the company’s 
willingness to negotiate is obvious. To investigate if NICE recommended drugs with 
simple discount schemes affect pricing elsewhere in Europe, we compared their list 
prices in France, Germany, Italy and the UK. The analysis focused on pharmaceu-
ticals recommended after 1 January 2011. Results: Since 2011, 20 therapies were 
recommended by NICE with a PAS based on a simple discount. In all except one case, 
the UK list price was the lowest among available list prices in all countries analysed. 
Where an Italian list price was available it was usually the highest. When compar-
ing the prices on an ex-manufactory level, the UK prices remain the lowest, but the 
German prices are generally the most expensive in this scenario. Of the countries 
analysed, only Italy has a risk sharing framework in place besides the UK. Out of the 
20 therapies analysed here, only 3 were under an Italian scheme. cOnclusiOns: 
The analysis shows that even before a PAS discount is applied, the UK price is 
already low, usually the lowest in the 4 EU countries analysed. There were no clear 
IPSG.1; identify patients correctly (criteria 1) and MMU.1& MMU.7; identify medi-
cation use & monitoring (criteria 2) Average for conforming to both criteria was 
calculated for each hospital. Correlation was tested between compliance to both 
criteria and hospital characteristics which were hospital type; general/tertiary & 
hospital geographical location; urban/rural. For each criterion; several measurables 
were selected from literature; and their average was calculated accordingly. Criteria 
1; 1 measurable, composed of 2 components of which there average was calcu-
lated. Criteria 2; 2 measurables; measurable for MMU.1 composed of 3 components, 
while measurable for MMU.7 composed of 2 components. Average of averages was 
calculated. Results: A total of 89.47% were complying to criteria 1 &10.53% non-
complying with 10 hospitals 100% conforming. 52.63% were complying to criteria 
2& 47.37% non-complying. Average compliance percentage with criteria 1 was 97.75, 
85.91& 98.25 for general rural, general urban and tertiary urban hospitals respec-
tively. In case of criteria 2, it was 28.75, 27.18& 20.5 for general rural, general urban 
and tertiary urban hospitals respectively. Correlations could not be established, no 
significant difference in means of compliance between or within criteria for dif-
ferent geographical locations or different hospital types; this can be contributed to 
the small sample size. cOnclusiOns: A baseline for comparison of compliance 
to safety-related approach in Saudi Arabia was established which can be used for 
comparison in future studies.
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Objectives: Serving 172,709 dispensing points, the pharmaceutical wholesale-
industry is a vital branch. One of the major business-objectives is total-customer-
satisfaction. Thus, a questionnaire aimed to draw a comprehensive picture of 
the level of satisfaction (including delivery-times and country-specific-issues) of 
pharmacists with pharmaceutical-full-line and short-line wholesalers, Direct-
sales from manufacturers, Direct-to-Pharmacies (DTP) and Reduced-Wholesale-
Arrangements (RWA) in Europe, focusing on Germany, UK., France, Spain and 
The Netherlands. MethOds: The necessary data was obtained from an online-
questionnaire (March 2011-October 2011) which was directed to pharmacies 
(n= 473). Results: The majority of the observed countries (99% in Spain to 72% 
in the UK) of the respondent pharmacists were satisfied with the distribution 
through pharmaceutical-full-line-wholesalers. With regard to the delivery-time 
offered by pharmaceutical-full-line wholesalers the satisfaction ranged from 97% 
in Spain to 76% in the UK. With regard to the distribution through short-line-
wholesalers 62.50% of the German pharmacists were satisfied. With their delivery-
time 56.30% of the pharmacists were satisfied, whereas 50.00% (distribution) and 
38.90% (delivery-time) of the Dutch-participants showed satisfaction. Less than 
half of the respondents (58% in Spain to 12% in the UK) in four out of the five 
countries observed showed satisfaction with the distribution through Direct-sales 
from manufactures. 80% of the pharmacists in the UK were unsatisfied with this 
kind of distribution-system. Concerning the delivery-time pharmacists in the 
majority of the observed countries answered with neutral. Pharmacists in the 
UK (76%) were unsatisfied with Direct-sales from manufacturer. Pharmacists in 
the UK were unsatisfied with Direct-to-Pharmacy and the Reduced-Wholesale-
Arrangements (DTP: 89.70% distribution vs. 75.90% delivery-time; RWA: 90.80% 
distribution vs. 58.50% delivery-time). Country-specific-issues mentioned were 
lack-of-availability of medicinal-products, stock-problems (UK), out-of-stocks 
problems (NL), shortages, supply-problems (ES) and decrease in discount-rates 
(DE). cOnclusiOns: The satisfaction of pharmacists varies greatly between dif-
ferent distribution-models. Responding pharmacists in the countries observed 
receiving their medicinal-products through pharmaceutical full-line-wholesalers 
showed overall-satisfaction with this kind of distribution-system.
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Objectives: Until March 2013,decisions on Individual funding requests (IFRs) had 
been the job of the primary care trusts to decide upon such requests. It has been 
widely acknowledged that IFRs to fund particular treatments have caused PCTs 
some thorny problems (with the rate of acceptance of IFRs having fallen from 59% in 
2008/09 to 46% in 2010/11). However, with the Clinical Commissioning Groups (CCGs) 
formally assuming commissioning responsibilities for their local populations since 
April 2013, it is expected that health services and care pathways will become more 
patient focussed. The objective of this study was to assess whether IFRs will enjoy 
better success under the so-called ‘patient centred’ CCG leadership. MethOds: 
This research was based on a combination of secondary and primary research to 
assess the CCGs attitudes and expertise to cope with IFRs. Secondary research of 
published data such as current IFR policies and overall CCG health care priorities 
contributed towards a framework to understand the key factors affecting success-
ful management of IFRs, which was then validated through a telephone survey 
of health care stakeholders. Results: CCGs understand the importance and the 
value of having a clear and robust IFR policy. Learning from PCTs, CCGs also realise 
that having a clear IFR standard operating procedures and clear timeframes would 
mean spending significantly less time considering and defending decisions on IFRs. 
Some CCGs also believe that public conversation may be required IFRs are to be 
managed effectively. cOnclusiOns: While CCGs realise that IFRs would be one 
of complicated bit of commissioning responsibilities, their real challenge is avoid 
making the same mistakes as PCTs. Early engagement with local populations about 
commissioning priorities is perceived to be crucial. Also the success of IFRs depends 
on organisations such as NHS Clinical Commissioners due to their dual role as CCG 
supporter and a body accountable to government.
